• Politics
  • Business
  • World
  • Science
  • Startup
  • Health
  • Travel
  • Economy
  • Top Story
Aryavarth News
  • Home
  • Politics
  • City News
  • Top Story
  • Editorial
Tuesday, February 7, 2023
No Result
View All Result
Aryavarth News
No Result
View All Result

Clinical Trials of AstraZeneca Oxford COVID-19 Vaccine Stopped In India

AstraZeneca Oxford COVID-19
427
VIEWS
Share on WhatsappShare on FacebookShare on TwitterShare on Telegram

Pune( Aryavarth): Serum Institute of India (SII) on Thursday said it is pausing clinical trials of AstraZeneca Oxford COVID-19 vaccine candidate in the country.

Earlier this week, AstraZeneca said it had paused the trials because of ‘an unexplained illness’ in a participant in the study.

RelatedPosts

No Content Available

However, SII on Wednesday said it was continuing with the trials and had not faced any issues.

SII’s latest announcement also comes against the backdrop of the central drug regulator DCGI issuing a show-cause notice to SII for not informing it about AstraZeneca pausing the clinical trials of the Oxford vaccine candidate in other countries.

“We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials,” SII said in a statement.

The Pune-based vaccine maker also said it is following instructions of the Drugs Controller General of India (DCGI), it added. In the show-cause notice, DCGI V G Somani had asked SII as to why the permission granted for conducting phase 2 and 3 clinical trials of the vaccine candidate in the country be not suspended till patient safety is established.

Tags: AstraZeneca Oxford COVID-19
SendShare39Tweet25Share

Related Posts

No Content Available
Aryavarth News

Copyright © 2022 Aryavarth Publication Pvt Ltd.

Navigate Site

  • About
  • Advertise
  • Privacy & Policy
  • Contact

Follow Us

No Result
View All Result
  • Politics
  • Business
  • World
  • Science
  • Startup
  • Health
  • Travel
  • Economy
  • Top Story

Copyright © 2022 Aryavarth Publication Pvt Ltd.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.